Annual FCF
-$44.62 M
-$12.27 M-37.94%
31 December 2023
Summary:
Aptose Biosciences annual free cash flow is currently -$44.62 million, with the most recent change of -$12.27 million (-37.94%) on 31 December 2023. During the last 3 years, it has fallen by -$10.65 million (-31.35%). APTO annual FCF is now -1727.52% below its all-time high of -$2.44 million, reached on 31 May 1999.APTO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$10.38 M
-$4.60 M-79.58%
30 September 2024
Summary:
Aptose Biosciences quarterly free cash flow is currently -$10.38 million, with the most recent change of -$4.60 million (-79.58%) on 30 September 2024. Over the past year, it has increased by +$160.00 thousand (+1.52%). APTO quarterly FCF is now -3853.98% below its all-time high of $276.40 thousand, reached on 31 May 1999.APTO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$37.18 M
+$160.00 K+0.43%
30 September 2024
Summary:
Aptose Biosciences TTM free cash flow is currently -$37.18 million, with the most recent change of +$160.00 thousand (+0.43%) on 30 September 2024. Over the past year, it has increased by +$6.83 million (+15.53%). APTO TTM FCF is now -3872.22% below its all-time high of -$935.90 thousand, reached on 31 August 1997.APTO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -37.9% | +1.5% | +15.5% |
| 3 y3 years | -31.4% | -25.9% | +1.7% |
| 5 y5 years | -89.6% | -98.5% | -76.2% |
APTO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -37.9% | at low | -79.6% | +35.4% | -14.9% | +17.5% |
| 5 y | 5 years | -106.0% | at low | -98.5% | +35.4% | -76.2% | +17.5% |
| alltime | all time | -1727.5% | at low | -3854.0% | +35.4% | -3872.2% | +17.5% |
Aptose Biosciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.38 M(+79.6%) | -$37.18 M(-0.4%) |
| June 2024 | - | -$5.78 M(-50.9%) | -$37.34 M(-17.2%) |
| Mar 2024 | - | -$11.76 M(+27.0%) | -$45.08 M(+1.0%) |
| Dec 2023 | -$44.62 M(+37.9%) | -$9.26 M(-12.1%) | -$44.62 M(+1.4%) |
| Sept 2023 | - | -$10.54 M(-22.1%) | -$44.01 M(+8.8%) |
| June 2023 | - | -$13.52 M(+19.6%) | -$40.45 M(+19.0%) |
| Mar 2023 | - | -$11.30 M(+30.6%) | -$34.00 M(+5.1%) |
| Dec 2022 | -$32.35 M(-25.7%) | -$8.65 M(+24.0%) | -$32.35 M(-18.6%) |
| Sept 2022 | - | -$6.98 M(-1.3%) | -$39.75 M(-3.1%) |
| June 2022 | - | -$7.07 M(-26.7%) | -$41.01 M(-4.1%) |
| Mar 2022 | - | -$9.64 M(-39.9%) | -$42.77 M(-1.7%) |
| Dec 2021 | -$43.52 M(+28.1%) | -$16.06 M(+94.9%) | -$43.52 M(+15.0%) |
| Sept 2021 | - | -$8.24 M(-6.6%) | -$37.84 M(-0.1%) |
| June 2021 | - | -$8.82 M(-15.1%) | -$37.88 M(+4.5%) |
| Mar 2021 | - | -$10.39 M(+0.2%) | -$36.24 M(+6.7%) |
| Dec 2020 | -$33.97 M(+56.8%) | -$10.38 M(+25.2%) | -$33.97 M(+13.9%) |
| Sept 2020 | - | -$8.29 M(+15.4%) | -$29.83 M(+11.4%) |
| June 2020 | - | -$7.18 M(-11.7%) | -$26.77 M(+7.6%) |
| Mar 2020 | - | -$8.13 M(+30.2%) | -$24.89 M(+14.9%) |
| Dec 2019 | -$21.66 M(-8.0%) | -$6.24 M(+19.4%) | -$21.66 M(+2.7%) |
| Sept 2019 | - | -$5.23 M(-1.3%) | -$21.10 M(+3.6%) |
| June 2019 | - | -$5.29 M(+8.1%) | -$20.37 M(-16.4%) |
| Mar 2019 | - | -$4.90 M(-13.8%) | -$24.36 M(+3.5%) |
| Dec 2018 | -$23.54 M(+129.9%) | -$5.68 M(+26.3%) | -$23.54 M(+13.7%) |
| Sept 2018 | - | -$4.50 M(-51.6%) | -$20.70 M(+13.1%) |
| June 2018 | - | -$9.28 M(+127.6%) | -$18.29 M(+57.0%) |
| Mar 2018 | - | -$4.08 M(+43.6%) | -$11.65 M(+13.9%) |
| Dec 2017 | -$10.24 M(-17.4%) | -$2.84 M(+35.8%) | -$10.22 M(-0.8%) |
| Sept 2017 | - | -$2.09 M(-20.8%) | -$10.31 M(-2.7%) |
| June 2017 | - | -$2.64 M(-0.5%) | -$10.60 M(-8.3%) |
| Mar 2017 | - | -$2.65 M(-9.2%) | -$11.56 M(-6.7%) |
| Dec 2016 | -$12.39 M(+22.1%) | -$2.92 M(+22.8%) | -$12.39 M(-2.3%) |
| Sept 2016 | - | -$2.38 M(-34.0%) | -$12.69 M(+7.0%) |
| June 2016 | - | -$3.60 M(+3.4%) | -$11.85 M(+0.5%) |
| Mar 2016 | - | -$3.49 M(+8.5%) | -$11.80 M(+16.2%) |
| Dec 2015 | -$10.15 M(+70.2%) | -$3.21 M(+108.1%) | -$10.15 M(+46.4%) |
| Sept 2015 | - | -$1.54 M(-56.5%) | -$6.93 M(+28.7%) |
| June 2015 | - | -$3.55 M(+93.0%) | -$5.39 M(-3.4%) |
| Mar 2015 | - | -$1.84 M(-50.8%) | -$5.58 M(-29.3%) |
| Dec 2014 | -$5.96 M(-24.4%) | - | - |
| May 2014 | -$7.89 M(+59.7%) | -$3.74 M(+100.2%) | -$7.89 M(+57.9%) |
| Feb 2014 | - | -$1.87 M(+33.8%) | -$5.00 M(+16.6%) |
| Nov 2013 | - | -$1.40 M(+57.7%) | -$4.29 M(+1.2%) |
| Aug 2013 | - | -$885.00 K(+4.3%) | -$4.24 M(-14.2%) |
| May 2013 | -$4.94 M(+53.7%) | -$848.60 K(-26.6%) | -$4.94 M(+13.3%) |
| Feb 2013 | - | -$1.16 M(-14.1%) | -$4.36 M(+1.0%) |
| Nov 2012 | - | -$1.35 M(-15.2%) | -$4.31 M(+16.7%) |
| Aug 2012 | - | -$1.59 M(+491.9%) | -$3.70 M(+15.1%) |
| May 2012 | -$3.21 M(-46.2%) | -$268.10 K(-75.9%) | -$3.21 M(-17.8%) |
| Feb 2012 | - | -$1.11 M(+52.7%) | -$3.91 M(-15.8%) |
| Nov 2011 | - | -$729.10 K(-33.9%) | -$4.64 M(-28.0%) |
| Aug 2011 | - | -$1.10 M(+14.6%) | -$6.45 M(+8.0%) |
| May 2011 | -$5.97 M | -$962.00 K(-47.9%) | -$5.97 M(+13.7%) |
| Feb 2011 | - | -$1.85 M(-27.1%) | -$5.25 M(+2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2010 | - | -$2.53 M(+305.3%) | -$5.14 M(+58.0%) |
| Aug 2010 | - | -$625.20 K(+155.9%) | -$3.25 M(-7.8%) |
| May 2010 | -$3.53 M(-47.9%) | -$244.30 K(-85.9%) | -$3.53 M(-35.5%) |
| Feb 2010 | - | -$1.73 M(+167.7%) | -$5.47 M(+7.6%) |
| Nov 2009 | - | -$647.50 K(-28.2%) | -$5.08 M(-13.0%) |
| Aug 2009 | - | -$901.20 K(-58.8%) | -$5.84 M(-13.8%) |
| May 2009 | -$6.78 M(-34.2%) | -$2.19 M(+62.6%) | -$6.78 M(-6.2%) |
| Feb 2009 | - | -$1.35 M(-4.2%) | -$7.22 M(-16.3%) |
| Nov 2008 | - | -$1.41 M(-23.6%) | -$8.63 M(-12.7%) |
| Aug 2008 | - | -$1.84 M(-30.2%) | -$9.89 M(-4.1%) |
| May 2008 | -$10.31 M(+74.6%) | -$2.63 M(-4.4%) | -$10.31 M(+24.6%) |
| Feb 2008 | - | -$2.75 M(+3.5%) | -$8.28 M(+18.7%) |
| Nov 2007 | - | -$2.66 M(+17.8%) | -$6.97 M(+6.9%) |
| Aug 2007 | - | -$2.26 M(+276.6%) | -$6.52 M(+10.5%) |
| May 2007 | -$5.90 M(-50.5%) | -$600.20 K(-58.6%) | -$5.90 M(-20.2%) |
| Feb 2007 | - | -$1.45 M(-34.5%) | -$7.40 M(-22.9%) |
| Nov 2006 | - | -$2.21 M(+34.9%) | -$9.59 M(+1.3%) |
| Aug 2006 | - | -$1.64 M(-21.6%) | -$9.47 M(-20.7%) |
| May 2006 | -$11.93 M(-22.5%) | -$2.09 M(-42.5%) | -$11.93 M(-5.9%) |
| Feb 2006 | - | -$3.64 M(+74.0%) | -$12.68 M(+4.3%) |
| Nov 2005 | - | -$2.09 M(-49.1%) | -$12.16 M(-18.5%) |
| Aug 2005 | - | -$4.11 M(+44.7%) | -$14.92 M(-3.1%) |
| May 2005 | -$15.40 M(-26.3%) | -$2.84 M(-9.1%) | -$15.40 M(-20.2%) |
| Feb 2005 | - | -$3.12 M(-35.6%) | -$19.30 M(-6.8%) |
| Nov 2004 | - | -$4.85 M(+5.7%) | -$20.70 M(-2.2%) |
| Aug 2004 | - | -$4.59 M(-32.0%) | -$21.16 M(+1.3%) |
| May 2004 | -$20.88 M(+117.6%) | -$6.74 M(+49.1%) | -$20.88 M(+23.7%) |
| Feb 2004 | - | -$4.52 M(-14.9%) | -$16.88 M(+10.2%) |
| Nov 2003 | - | -$5.31 M(+23.3%) | -$15.32 M(+26.5%) |
| Aug 2003 | - | -$4.31 M(+56.8%) | -$12.11 M(+26.2%) |
| May 2003 | -$9.59 M(+18.4%) | -$2.75 M(-7.1%) | -$9.59 M(+4.1%) |
| Feb 2003 | - | -$2.96 M(+40.7%) | -$9.22 M(-2.6%) |
| Nov 2002 | - | -$2.10 M(+17.5%) | -$9.46 M(+20.1%) |
| Aug 2002 | - | -$1.79 M(-24.4%) | -$7.88 M(-2.8%) |
| May 2002 | -$8.10 M(+26.7%) | -$2.37 M(-26.0%) | -$8.10 M(+13.9%) |
| Feb 2002 | - | -$3.20 M(+513.9%) | -$7.12 M(+20.6%) |
| Nov 2001 | - | -$521.20 K(-74.1%) | -$5.90 M(-8.6%) |
| Aug 2001 | - | -$2.02 M(+45.9%) | -$6.46 M(+1.0%) |
| May 2001 | -$6.40 M(-13.2%) | -$1.38 M(-30.3%) | -$6.40 M(+27.7%) |
| Feb 2001 | - | -$1.98 M(+84.2%) | -$5.01 M(-49.5%) |
| Nov 2000 | - | -$1.08 M(-44.8%) | -$9.92 M(+9.6%) |
| Aug 2000 | - | -$1.95 M(<-9900.0%) | -$9.05 M(+22.9%) |
| May 2000 | -$7.37 M(+201.8%) | $5800.00(-100.1%) | -$7.37 M(+3.8%) |
| Feb 2000 | - | -$6.90 M(+3221.4%) | -$7.10 M(+450.5%) |
| Nov 1999 | - | -$207.70 K(-22.4%) | -$1.29 M(-21.1%) |
| Aug 1999 | - | -$267.60 K(-196.8%) | -$1.63 M(-33.1%) |
| May 1999 | -$2.44 M(-22.7%) | $276.40 K(-125.4%) | -$2.44 M(-27.0%) |
| Feb 1999 | - | -$1.09 M(+97.6%) | -$3.35 M(+1.1%) |
| Nov 1998 | - | -$551.90 K(-48.7%) | -$3.31 M(+0.4%) |
| Aug 1998 | - | -$1.08 M(+71.2%) | -$3.30 M(+4.4%) |
| May 1998 | -$3.16 M(+20.9%) | -$628.50 K(-40.4%) | -$3.16 M(+24.8%) |
| Feb 1998 | - | -$1.05 M(+95.2%) | -$2.53 M(+71.4%) |
| Nov 1997 | - | -$539.80 K(-42.3%) | -$1.48 M(+57.7%) |
| Aug 1997 | - | -$935.90 K | -$935.90 K |
| May 1997 | -$2.61 M | - | - |
FAQ
- What is Aptose Biosciences annual free cash flow?
- What is the all time high annual FCF for Aptose Biosciences?
- What is Aptose Biosciences annual FCF year-on-year change?
- What is Aptose Biosciences quarterly free cash flow?
- What is the all time high quarterly FCF for Aptose Biosciences?
- What is Aptose Biosciences quarterly FCF year-on-year change?
- What is Aptose Biosciences TTM free cash flow?
- What is the all time high TTM FCF for Aptose Biosciences?
- What is Aptose Biosciences TTM FCF year-on-year change?
What is Aptose Biosciences annual free cash flow?
The current annual FCF of APTO is -$44.62 M
What is the all time high annual FCF for Aptose Biosciences?
Aptose Biosciences all-time high annual free cash flow is -$2.44 M
What is Aptose Biosciences annual FCF year-on-year change?
Over the past year, APTO annual free cash flow has changed by -$12.27 M (-37.94%)
What is Aptose Biosciences quarterly free cash flow?
The current quarterly FCF of APTO is -$10.38 M
What is the all time high quarterly FCF for Aptose Biosciences?
Aptose Biosciences all-time high quarterly free cash flow is $276.40 K
What is Aptose Biosciences quarterly FCF year-on-year change?
Over the past year, APTO quarterly free cash flow has changed by +$160.00 K (+1.52%)
What is Aptose Biosciences TTM free cash flow?
The current TTM FCF of APTO is -$37.18 M
What is the all time high TTM FCF for Aptose Biosciences?
Aptose Biosciences all-time high TTM free cash flow is -$935.90 K
What is Aptose Biosciences TTM FCF year-on-year change?
Over the past year, APTO TTM free cash flow has changed by +$6.83 M (+15.53%)